Press Releases

Date Title and Summary Additional Formats
Toggle Summary Chromos and Xencor announce agreement for use of the ACE System to produce biologics.
Chromos and Xencor announce agreement for use of the ACE System to produce biologics. Burnaby, British Columbia, Canada and Monrovia, California, United States – Chromos Molecular Systems Inc. (“Chromos“ TSX: CHR) and Xencor announced today that they have entered into a non-exclusive research
View HTML
Toggle Summary Bassil Dahiyat Named One of the World’s Top Young Innovators
Bassil Dahiyat Named One of the World’s Top Young Innovators by Technology Review, MIT’s Magazine of Innovation. Dahiyat To Be Honored September 24-25 at The Emerging Technologies Conference at MIT
View HTML
Toggle Summary Xencor Receives Advanced Technology Program Grant For Safer Protein Therapeutics
(BW Healthwire)–October 09, 2002—Grant to Support the Rational Design of Non-immunogenic Proteins
View HTML
Toggle Summary Xencor Reaches Research Milestone
Xencor Reaches Research Milestone (BW Healthwire)–June 17, 2002—Monrovia, CA – Xencor today announced that it has reached a major milestone in its research agreement with Syngenta’s (NYSE: SYT) Torrey Mesa Research Institute (TMRI). In just six months, half the time agreed upon, Xencor has created
View HTML
Toggle Summary Enhancing The Therapeutic Utility of Biopharmaceuticals: The Next Frontier
Enhancing The Therapeutic Utility of Biopharmaceuticals: The Next Frontier (BW Healthwire)–June 04, 2002—Xencor’s Vice President, Discovery Technologies, Robert Pacifici, Ph.D., Presents at BIO 2002, June 10 at 10:30 a.m.-12:00 p.m. in room 701A. Monrovia, CA – Xencor, a drug discovery company
View HTML
Toggle Summary Xencor Optimizes Key Pharmaceutical Proteins
(BW Healthwire)–May 29, 2002—Xencor’s Protein Design Technology Provides Superior Control and Flexibility in Biotherapeutic Creation
View HTML
Toggle Summary Chemical Genomics – CALBIOsummit 2002 April 21,22,23
(BW Healthwire)–April 18, 2002—Xencor’s President and CEO, Dr. Bassil Dahiyat Chairs Panel at CALBIOsummit 2002
View HTML
Toggle Summary Xencor Licenses Patent For Chemical Genomics Technology Profiling Biological And Pharmacological Interactions
(BW Healthwire)–March 11, 2002—Xencor President and CEO Presents at SG Cowen Health Care Conference Today at 10:00 am EST
View HTML
Toggle Summary Xencor Expands Protein Optimization Technology To Develop Next-Generation Biotechnology Products
Xencor Expands Protein Optimization Technology To Develop Next-Generation Biotechnology Products (BW Healthwire)–February 20, 2002—Monrovia, CA – February 20, 2002 – Xencor today announced that it has signed licensing agreements with the California Institute of Technology and Pennsylvania State
View HTML
Toggle Summary Syngenta’s Torrey Mesa Research Institute And Xencor Sign Research And License Agreement
Syngenta’s Torrey Mesa Research Institute And Xencor Sign Research And License Agreement (BW Healthwire)–January 03, 2002—La Jolla, CA and Monrovia, CA.- January 3, 2002 -Torrey Mesa Research Institute (TMRI), a wholly owned subsidiary of Syngenta (NYSE: SYT), today announced the signing of a three
View HTML
Xencor © Copyright 2018